CAR T-cell therapy for solid tumours may advance cancer treatments

Google+ Pinterest LinkedIn Tumblr +

Immunotherapy with genetically modified lymphocytes, such as CAR-T cells, is one of the most promising branches of modern fundamental and clinical oncology.

A CAR-T cell is a T-lymphocyte with a gene encoding a chimeric antigen receptor, or CAR receptor, in its genome.

“To simplify the concept, we can say that a T-cell is a soldier of the regular forces, and a CAR-T cells are special forces performing particularly difficult tasks. At the same time, CAR-T cells can be ‘given a command’ to destroy almost any type of tumour,” explained project lead Emil Bulatov, Associate Professor at the Department of Biochemistry, Biotechnology and Pharmacology, Leading Research Associate at the Gene and Cell Technology Lab, Kazan University, Russia.

The process is as follows: tumour cells contain certain “beacon” proteins on their surface, by which CAR-T cells can find them in the human body and destroy them.

In the case of haematologic diseases, one of these proteins is CD19, which is located on the surface of B cells.

In the case of solid tumours, the HER2, PCSA, ROR1 proteins can serve as such beacons.

It is the fight against solid tumours that is one of the most complex and interesting problems in this area.

Currently, there are only two approved biomedical cell preparations based on CAR-T cells for the treatment of haematologic diseases in the world (tisagenlecleucel and axicabtagene ciloleucel).

However, despite the success of CAR-T cell therapy for the treatment of haematologic diseases, the question of its effective use against solid tumours (carcinoma, neuroblastoma, etc.) remains unresolved.

This is due to several reasons, such as high heterogeneity of the cell composition of solid tumours, immunosuppressive tumour microenvironment, difficulties in penetrating the tumour stroma, local hypoxia and a lack of nutrients inside the tumour.

Given the high prevalence of solid tumours, the search for ways to effectively use CAR-T immunotherapy for their treatment is extremely relevant.

“Together with colleagues, we have already conducted preliminary experiments on xenograft animal models with a seated tumour, and the results are very encouraging. The data obtained on cell models of solid tumours were generally confirmed in subsequent experiments with immunodeficient mice,” stated Bulatov.

The use of CAR-T cells was non-toxic to mice and resulted in a marked reduction in tumour size.

“We believe that this work will bring us closer to creating domestic CAR-T-cell preparations and to treating cancer patients. The first stages of translating our results into practice will be held at the Center for Precision and Regenerative Medicine of Kazan Federal University,” concluded the researcher.


Source: Kazan Federal University

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.